SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Phymatrics (PHMX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew Q. Viet who wrote (72)7/31/1997 10:51:00 PM
From: Tsquare   of 118
 
From July/Aug Physician's Practice Digest (info provided by Premier Health Care):

"The overall decline in the PPM sector could be particularly acute for PhyMatrix Corp. During 1996 PHMX completed six acquisitions for which it promised to deliver common stock worth $7.1 million between May and August 1997. The stock was trading around $23 per share when the deals were closed, but by the end of May was trading around $14, or 39 percent lower. As a result, PHMX will suffer further dilution, having to shell out nearly 200,000 additional shares.

Remember you heard it here first. . .Crafty PHMX chairman Abe Gosman will hit the road visiting institutional investors throughout the summer in an attempt to drive the price of PHMX shares. At a price in excess of $18 per share, we would not be surprised to see PHMX as the next gulp for ever-acquisitive MedPartners, Inc."

Is the dilution story true? Is a Medpartners take-over likely?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News